“…Various strategies have been developed to improve the bioavailability of small molecules, such as pharmaceutical salts, − cocrystals, pharmaceutical solvates, − gels, and compositions with polymers and cyclodextrins. − Several techniques have been proposed in the literature for improving the pharmaceutically relevant characteristics of FluBZ, including the use of ionic liquids, binary crystals, and nanoemulsions, as well as incorporation in cyclodextrin cavities. − Amorphization is one of the most commonly utilized methods for increasing the apparent solubility and permeability of an active pharmaceutical ingredient (API). , However, amorphous pharmaceuticals are thermodynamically unstable phases that tend to crystallize during manufacture, storage, and dissolution. , Development of a homogeneous single-phase co-amorphous system consisting of an API and a second component, on the other hand, efficiently suppresses crystallization, prolonging the shelf life of a product while keeping the benefits of the amorphous form . Furthermore, combining two synergistic APIs into a co-amorphous system may boost treatment efficiency, potentially leading to attractive fixed-dose combinations. , …”